SAN
JOSE, Calif., May 13, 2024
/PRNewswire/ -- Meditrina, a leading innovator in gynecologic
medical devices, announces the successful receipt of UKCA Mark, and
CE Mark approval in accordance with Regulation (EU) 20147/745, for
its state-of-the-art Aveta Hysteroscopy System. With this
significant milestone achieved, Meditrina is thrilled to enter
international markets, marking a pivotal moment in the company's
commitment to advancing women's health globally.
Receiving the UKCA and CE Mark approval underscores Meditrina's
dedication to meeting the highest standards of quality, safety, and
efficacy required for market entry in the European Union and the
UK. This achievement not only validates the company's commitment to
regulatory compliance but also positions Meditrina as a trusted
provider of cutting-edge medical solutions.
Hysteroscopy is a crucial diagnostic and therapeutic procedure
used to evaluate and treat conditions affecting the uterus.
Meditrina's Aveta hysteroscopy system combines advanced technology
with ergonomic design, enabling healthcare professionals to perform
minimally invasive procedures with enhanced visualization and
control, ultimately leading to improved patient outcomes and
experiences.
"We are excited to receive UKCA and CE Mark approval for our
hysteroscopy system, as it validates the exceptional quality and
performance of our product," remarked Csaba Truckai, CEO of
Meditrina. "Furthermore, the successful completion of our initial
international procedures in Spain
and Denmark signifies a
significant milestone in our mission to revolutionize women's
healthcare on a global scale. We are proud to collaborate with
healthcare providers worldwide in delivering advanced solutions
that empower women to lead healthier lives."
The appointment of Ray Gerena as
the Senior Vice President of Global Sales further strengthens
Meditrina's commitment to driving growth and expanding its global
footprint. With Ray's extensive experience and leadership in
strategic sales initiatives, Meditrina is well-positioned to
capitalize on new market opportunities and forge strong
partnerships with healthcare providers worldwide.
Ray remarked, "I am honored to join Meditrina at such an
exciting time in its journey. The UKCA and CE Mark approval and
successful international procedures represent significant
milestones for the company, and I am eager to lead our global sales
efforts in bringing our innovative hysteroscopy system to
healthcare providers around the world. Together, we will continue
to make a meaningful impact on women's health."
The inaugural international procedures conducted in Spain and Denmark exemplify the growing demand for
Meditrina's groundbreaking hysteroscopy system beyond the United States. Healthcare professionals in
Spain and Denmark have embraced the technology's
capabilities, recognizing its potential in the diagnosis and
treatment of various gynecological conditions while prioritizing
patient comfort and safety.
Through ongoing innovation and collaboration, Meditrina remains
steadfast in its commitment to empowering healthcare professionals
and improving outcomes for women worldwide.
About Meditrina:
Founded in 2016, Meditrina, Inc. designs and develops innovative
medical devices for minimally invasive gynecology. For more
information, visit www.avetasystem.com.
Contact:
Abbey Taylor
Associate VP of Marketing
abbeyt@meditrina-inc.com
SOURCE Meditrina Inc.
Aveta® is a registered trademark of Meditrina Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/meditrina-announces-ce-mark-approval-and-first-multi-international-cases-performed-302144145.html
SOURCE Meditrina, Inc.